In contrast to a previous RCAS TFG-MET-driven pHGG model [7], the allograft described here is studied in an immunocompetent, wild-type p53 host background and allows robust preclinical evaluation by standardized tumor cell transplantation. The gene discussed is TP53; the disease is neoplasm.